| 000 | 01712 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250516133713.0 | ||
| 264 | 0 | _c20130925 | |
| 008 | 201309s 0 0 eng d | ||
| 022 | _a1619-7089 | ||
| 024 | 7 |
_a10.1007/s00259-012-2330-6 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBodei, L | |
| 245 | 0 | 0 |
_aThe joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. _h[electronic resource] |
| 260 |
_bEuropean journal of nuclear medicine and molecular imaging _cMay 2013 |
||
| 300 |
_a800-16 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Practice Guideline | ||
| 650 | 0 | 4 | _aEurope |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInternational Agencies |
| 650 | 0 | 4 |
_aKidney _xphysiology |
| 650 | 0 | 4 |
_aMolecular Targeted Therapy _xadverse effects |
| 650 | 0 | 4 |
_aNeuroendocrine Tumors _xmetabolism |
| 650 | 0 | 4 | _aNuclear Energy |
| 650 | 0 | 4 | _aQuality Control |
| 650 | 0 | 4 | _aRadiometry |
| 650 | 0 | 4 |
_aRadiopharmaceuticals _xadverse effects |
| 650 | 0 | 4 |
_aRadiotherapy _xadverse effects |
| 650 | 0 | 4 |
_aReceptors, Peptide _xmetabolism |
| 650 | 0 | 4 | _aSocieties, Scientific |
| 700 | 1 | _aMueller-Brand, J | |
| 700 | 1 | _aBaum, R P | |
| 700 | 1 | _aPavel, M E | |
| 700 | 1 | _aHörsch, D | |
| 700 | 1 | _aO'Dorisio, M S | |
| 700 | 1 | _aO'Dorisio, T M | |
| 700 | 1 | _aO'Dorisiol, T M | |
| 700 | 1 | _aHowe, J R | |
| 700 | 1 | _aCremonesi, M | |
| 700 | 1 | _aKwekkeboom, D J | |
| 700 | 1 | _aZaknun, John J | |
| 773 | 0 |
_tEuropean journal of nuclear medicine and molecular imaging _gvol. 40 _gno. 5 _gp. 800-16 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s00259-012-2330-6 _zAvailable from publisher's website |
| 999 |
_c22485139 _d22485139 |
||